Steven R Bentley1, Stephanie Bortnick2, Ilaria Guella3, Javed Y Fowdar4, Peter A Silburn5, Stephen A Wood6, Matthew J Farrer7, George D Mellick8. 1. Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia. Electronic address: steven.bentley2@griffithuni.edu.au. 2. Djavad Mowafhagian Centre for Brain, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: sbortnick@can.ubc.ca. 3. Djavad Mowafhagian Centre for Brain, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: iguella@can.ubc.ca. 4. Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia. Electronic address: j.fowdar@griffith.edu.au. 5. Centre for Clinical Research, University of Queensland, Brisbane, Queensland, Australia. Electronic address: p.silburn@uq.edu.au. 6. Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia. Electronic address: s.wood@griffith.edu.au. 7. Djavad Mowafhagian Centre for Brain, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: mfarrer@can.ubc.ca. 8. Griffith Institute for Drug Discovery, Griffith University, Don Young Road, Nathan, Queensland, Australia. Electronic address: g.mellick@griffith.edu.au.
Abstract
INTRODUCTION: Family based study designs provide an informative resource to identify disease-causing mutations. The Queensland Parkinson's Project (QPP) has been involved in numerous genetic screening studies; however, details of the families enrolled into the register have not been comprehensively reported. This article characterises the families enrolled in the QPP and summarises monogenic forms of hereditary Parkinsonism found in the register. METHOD: The presence of pathogenic point mutations and copy number variations (CNVs) were, generally, screened in a sample of over 1000 PD patients from the total of 1725. Whole exome sequencing (WES) was performed on eighteen probands from multiplex families. RESULTS: The QPP contains seventeen incidences of confirmed monogenic forms of PD, including LRRK2 p.G2019S, VPS35 p.D620N, SNCA duplications and PARK2 p.G430D (hom) & exon 4 deletion (hom). Of these seventeen, five belong to multi-incident families, while another eight have a family history of at least one other case of PD. In additional families, WES did not identify known forms of monogenic Parkinsonism; however, three heterozygous mutations in PARK2, p.R275W, p.Q34fs, and a 40bp deletion in exon 3 were identified. Of these three mutations, only the 40bp deletion segregated with disease in a dominant inheritance pattern. CONCLUSION: Eighteen probands have screened negative for known CNVs and mutations that cause clear monogenic forms of PD. Each family is a candidate for further genetic analysis to identify genetic variants segregating with disease. The families enrolled in the QPP provide a useful resource to aid in identifying novel forms of monogenic PD.
INTRODUCTION: Family based study designs provide an informative resource to identify disease-causing mutations. The Queensland Parkinson's Project (QPP) has been involved in numerous genetic screening studies; however, details of the families enrolled into the register have not been comprehensively reported. This article characterises the families enrolled in the QPP and summarises monogenic forms of hereditary Parkinsonism found in the register. METHOD: The presence of pathogenic point mutations and copy number variations (CNVs) were, generally, screened in a sample of over 1000 PDpatients from the total of 1725. Whole exome sequencing (WES) was performed on eighteen probands from multiplex families. RESULTS: The QPP contains seventeen incidences of confirmed monogenic forms of PD, including LRRK2p.G2019S, VPS35 p.D620N, SNCA duplications and PARK2p.G430D (hom) & exon 4 deletion (hom). Of these seventeen, five belong to multi-incident families, while another eight have a family history of at least one other case of PD. In additional families, WES did not identify known forms of monogenic Parkinsonism; however, three heterozygous mutations in PARK2, p.R275W, p.Q34fs, and a 40bp deletion in exon 3 were identified. Of these three mutations, only the 40bp deletion segregated with disease in a dominant inheritance pattern. CONCLUSION: Eighteen probands have screened negative for known CNVs and mutations that cause clear monogenic forms of PD. Each family is a candidate for further genetic analysis to identify genetic variants segregating with disease. The families enrolled in the QPP provide a useful resource to aid in identifying novel forms of monogenic PD.
Authors: Daniel Kam Yin Chan; Jack Chen; Ren Fen Chen; Jayesh Parikh; Ying Hua Xu; Peter A Silburn; George D Mellick Journal: J Neurol Date: 2022-07-25 Impact factor: 6.682
Authors: Svetlana Bivol; George D Mellick; Jacob Gratten; Richard Parker; Aoibhe Mulcahy; Philip E Mosley; Peter C Poortvliet; Adrian I Campos; Brittany L Mitchell; Luis M Garcia-Marin; Simone Cross; Mary Ferguson; Penelope A Lind; Danuta Z Loesch; Peter M Visscher; Sarah E Medland; Clemens R Scherzer; Nicholas G Martin; Miguel E Rentería Journal: BMJ Open Date: 2022-02-25 Impact factor: 3.006
Authors: Melissa A Hill; Steven R Bentley; Tara L Walker; George D Mellick; Stephen A Wood; Alex M Sykes Journal: PLoS One Date: 2022-07-28 Impact factor: 3.752
Authors: Steven R Bentley; Ilaria Guella; Holly E Sherman; Hannah M Neuendorf; Alex M Sykes; Javed Y Fowdar; Peter A Silburn; Stephen A Wood; Matthew J Farrer; George D Mellick Journal: Genes (Basel) Date: 2021-03-17 Impact factor: 4.096
Authors: Zoé Hanss; Simone B Larsen; Paul Antony; Pauline Mencke; François Massart; Javier Jarazo; Jens C Schwamborn; Peter A Barbuti; George D Mellick; Rejko Krüger Journal: Mov Disord Date: 2020-11-03 Impact factor: 10.338